The Venture Codex Logo

The Venture Codex

Overview

Innovative pharmaceutical company specializing in neurological treatments.

Founded

1908

Deals · 12mo

0

Stage focus

Series B

Geographic focus

Israel
United States

Sector focus

Biotechnology

Investment portfolio

3rounds
NAMEDATESIZE
Vensica Medical
Oct 2024Participated
$11 MOther Equity
Vensica Medical
Feb 2022Participated
$19 MOther Equity
Cytrellis Biosystems
Jun 2018Participated
$29 MSeries B
Vensica Medical
Oct 2024Participated
$11 MOther Equity
Vensica Medical
Feb 2022Participated
$19 MOther Equity
Cytrellis Biosystems
Jun 2018Participated
$29 MSeries B
3
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Merz: 3 funding rounds are recorded in the selected participation categories.All available history.
Merz: 3 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series B01
Other Equity02

Monthly Deal Activity

Merz: 3 deals are recorded across 101 months.All available history.
Merz: 3 deals are recorded across 101 months. All available history
MonthDeals
Jun '181
Jul '180
Aug '180
Sep '180
Oct '180
Nov '180
Dec '180
Jan '190
Feb '190
Mar '190
Apr '190
May '190
Jun '190
Jul '190
Aug '190
Sep '190
Oct '190
Nov '190
Dec '190
Jan '200
Feb '200
Mar '200
Apr '200
May '200
Jun '200
Jul '200
Aug '200
Sep '200
Oct '200
Nov '200
Dec '200
Jan '210
Feb '210
Mar '210
Apr '210
May '210
Jun '210
Jul '210
Aug '210
Sep '210
Oct '210
Nov '210
Dec '210
Jan '220
Feb '221
Mar '220
Apr '220
May '220
Jun '220
Jul '220
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '230
Feb '230
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '240
Oct '241
Nov '240
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Merz: Health & Life Sciences is the largest displayed sector by deal count (3 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Merz: Health & Life Sciences is the largest displayed sector by deal count (3 deals). All available history
SectorDeals
Health & Life Sciences3

Deal Size Distribution

Merz: 3 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Merz: 3 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M0
$10M-$25M2
$25M-$50M1
$50M-$100M0
$100M-$250M0
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

Merz: Israel has the largest recorded deal count among the displayed regions (2 deals).All available history.

Top 2 of 2 regions; European countries are grouped as Europe.

Merz: Israel has the largest recorded deal count among the displayed regions (2 deals). All available history
RegionDeals
Israel2
United States1
Merz: 7 co-investors are shown, with Israel Biotech Fund sharing 2 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Merz: 7 co-investors are shown, with Israel Biotech Fund sharing 2 recorded deals. All available history
Co-investorShared deals
Israel Biotech Fund2
Laborie Medical Technologies2
Agriline1
ARCH Venture Partners1
Biomatics Capital1
Partner Fund Management1
The Trendlines Group1

Investment Strategy

Merz: Led accounts for 0% and participating for 100% of round participation.All available history.
Merz: Led accounts for 0% and participating for 100% of round participation. All available history
CategoryDeals (count)Share (%)
Led00%
Participating3100%
Merz: Single-lead accounts for 0% and co-led for 0% of lead dynamics.All available history.
Merz: Single-lead accounts for 0% and co-led for 0% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead00%
Co-led00%

Lead dynamics requires at least one led deal in this range

Team

Bob Rhatigan

CEO, Merz Aesthetics

David Wohde

Head of Digital Transformation

Jane Royall

Director, Corporate Communications and Business Planning

Philip Burchard

Chief Executive Officer